<code id='1D637EBBBA'></code><style id='1D637EBBBA'></style>
    • <acronym id='1D637EBBBA'></acronym>
      <center id='1D637EBBBA'><center id='1D637EBBBA'><tfoot id='1D637EBBBA'></tfoot></center><abbr id='1D637EBBBA'><dir id='1D637EBBBA'><tfoot id='1D637EBBBA'></tfoot><noframes id='1D637EBBBA'>

    • <optgroup id='1D637EBBBA'><strike id='1D637EBBBA'><sup id='1D637EBBBA'></sup></strike><code id='1D637EBBBA'></code></optgroup>
        1. <b id='1D637EBBBA'><label id='1D637EBBBA'><select id='1D637EBBBA'><dt id='1D637EBBBA'><span id='1D637EBBBA'></span></dt></select></label></b><u id='1D637EBBBA'></u>
          <i id='1D637EBBBA'><strike id='1D637EBBBA'><tt id='1D637EBBBA'><pre id='1D637EBBBA'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:467
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Do more moles mean more problems? Not so, says new study
          Do more moles mean more problems? Not so, says new study

          Thenumberofmolesisnotagoodindicatorofcancer'saggressiveness.APStockDermatologistsconstantlyhammerhom

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          How to address the problem of discarded donor organs

          Adoctorflushesadonorkidneyduringatransplantprocedure.BRENDANSMIALOWSKI/AFP/GettyImagesAsIwasgettingr